Key appointment to support continued UK and US team expansion Cambridge, UK, 27 June 2024: CN Bio, a leading provider of single- and multi-organ microphysiological systems, today announced the appointment of Lydia Seymour as Vice President of People and Culture. In this role, Lydia will work alongside the Company’s management team, providing guidance and support across recruitment and employee wellbeing, in addition to ensuring the implementation of robust professional development plans for CN Bio’s growing global team, and driving new initiatives to enhance workplace culture. Lydia’s…

 AMSBIO has launched a Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line. GLP-1R is known to play a key role in controlling blood sugar levels by enhancing glucose-stimulated insulin secretion. Therefore, there is considerable interest in harnessing regulation of the GLP-1R mediated signaling pathway as a therapeutic approach to type 2 diabetes which has already resulted in the development of several GLP-1 FDA-approved agonists. In addition, GLP-1R agonists have also been shown to contribute to weight management, decrease the potential for cardiovascular diseases and…

 The June edition of our People Pathways newsletter is now available to read here. You will find: One Nucleus upcoming courses Our new BLSA SIG on Neurodiversity  A Blog by Tony Jones, CEO of One Nucleus Guest article by Aon  You can also read last month's newlsetter here.

Sandwich, Kent, UK / 26th June 2024 / Discovery Park welcomed experts in healthy ageing to its Innovation Summit on 20th June, calling for the life science network in Kent to join forces to make the county a leader in healthy ageing and longevity.  Over 230 attendees came together at the one day event to discuss innovation in healthcare, taking a close look at trends in healthy ageing, developing more integrated care, and the role of digital collaboration in future healthcare delivery. Over-85s are the UK's fastest growing age group. Healthy ageing needs both biomedical and societal…

Check out the latest EY Biotechnology Report 2024

UK Life Science Trend Analysis 2024 The UK government published the Science & Technology Framework in early 2023, signaling a robust strategy for the growth of the science and technology sector, with a focus on increasing private investment in R&D. Potentially a result of this strategic push, biotech private equity funding experienced a slight rise both in terms of the amount raised and the number of funding rounds completed. Biotechnology remains the primary focus within the UK life science industry, representing 36% of all companies. Notably, half of the biotech firms…

Press release Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development • Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems • The collaboration will combine advanced in vivo models with new therapeutic approaches to support Macomics’ continued exploration of novel macrophage biology for precision oncology medicines Edinburgh and Cambridge,…

Sandwich, Kent, UK / 18th June 2024 / Discovery Park, Kent’s thriving life science and innovation community, is preparing to welcome 300 healthcare innovators to its campus on Thursday 20th June for its second annual Innovation Summit, with only final spots remaining. This year’s summit has a focus on innovation in healthcare, taking a close look at trends in healthy ageing, breakthroughs in medicine and life science, and the role of digital collaboration in future healthcare delivery. The one day event at Discovery Park’s campus in Sandwich includes morning  keynote speeches from…

On Wednesday 15th May, Pharmaron hosted the 3rd Chemistry for Life Science Symposium. Academic and industry experts presented on the leading edge of drug discovery and process chemistry with speakers Professor Robert Phipps (University of Cambridge), Professor Ross Denton (University of Nottingham), Dr Sarah Skerratt (CHARM Therapeutics), Dr David Wilson (AstraZeneca), Dr Jeremy Parker (AstraZeneca) along with Dr Sébastien Campos (Pharmaron) and Dr Aaron Dumas (Pharmaron). The industry topics varied from early-stage drug discovery and the impact of AI, together with synthetic…

Accelerating Drug Discovery with the CCDC, AWS, and Intel: Curated Data Set of Protein Structures from the Protein Data Bank with Predicted Hydrogen Positions Now Available Cambridge, UK – 18 June 2024 – Thanks to the combined computing power of Amazon Web Services (AWS) and Intel, the CCDC announces that a potentially significant advancement in drug discovery has been achieved. A curated data set of protein structures from the Protein Data Bank (PDB) with predicted hydrogen positions is now available for download. This project was supported by an Intel RISE Technology Initiative contribution…